Study design
psychiatric, ASPD
The study was conducted with a randomized, double-blind, placebo-controlled within-subject design. After an extensive telephone screening, participants took part at an initial diagnostic assessment (including psychiatric evaluation and symptom/personality questionnaires). They were then invited to two experimental assessments, scheduled four weeks apart, at which they underwent functional magnetic resonance imaging (fMRI). The order of the drug administration was randomized by an independent pharmacist providing a computerized simple randomization list. Participants were instructed to abstain from nicotine, food, and drinks except water for 2 h before the experiment. Upon arrival, urine drug tests had to be negative except from tetrahydrocannabinol (THC) due to its dissemination in the general population and particularly in participants with ASPD [